Highlight
– In a multicenter randomized trial of low‑risk AMI patients who completed 1 month of uneventful DAPT after successful complete revascularization, switching to P2Y12‑inhibitor monotherapy was noninferior to continuing DAPT for a composite of ischemic and major bleeding outcomes at 11 months.
– P2Y12‑inhibitor monotherapy halved clinically relevant bleeding (BARC 2/3/5) compared with continued DAPT (2.6% vs 5.6%; HR 0.46; 95% CI 0.29–0.75), with similar ischemic event rates and rare stent thrombosis.
